Bone mineral density test followed by selective alendronate found to improve resource use

-- Lindsey Marcellin

Tuesday, May 18, 2010 (Last Updated: 05/20/2010)

TUESDAY, May 18 (HealthDay News) -- A bone mineral density test followed by selective use of alendronate for fracture prevention in men beginning androgen deprivation therapy for localized prostate cancer is cost-effective, according to research published in the May 18 issue of the Annals of Internal Medicine.

Kouta Ito, M.D., of Memorial Sloan-Kettering Cancer Center in New York City, and colleagues used modeling techniques to assess the cost-effectiveness of three alternative strategies for preventing fractures in a hypothetical cohort of men aged 70 years starting a two-year course of androgen deprivation therapy (ADT) for locally advanced or high-risk localized prostate cancer: bone mineral density (BMD) testing for all, with alendronate therapy for those men with osteoporosis; no screening and no alendronate treatment of any man; and universal alendronate treatment for all men undergoing ADT with a BMD test. The measured outcome was the incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life-year (QALY) gained.

For the strategy of using BMD testing followed by selective use of alendronate, the ICER was $66,800 per QALY gained. For the alternate strategy of universal alendronate therapy, the ICER was $178,700 per QALY gained. Factors that might lower the ICER and make universal alendronate more cost-effective were an assumption of older age, previous fracture history, lower pre-ADT BMD, and a lower cost of alendronate.

"These results are encouraging and suggest that prevention of bone loss with alendronate is cost-effective when treatment is targeted to patients at high risk for fractures. Our results also suggest that Medicare coverage of a BMD test could be expanded to this patient population. Future research should assess whether the effect of alendronate on BMD correlates with a reduction in fracture rates in this patient population," the authors write.

Abstract
Full Text (subscription or payment may be required)

Specialties Internal Medicine
Orthopedics
Hematology & Oncology
Geriatrics
Urology
Family Practice
Diabetes & Endocrinology

Copyright © 2010 HealthDay. All rights reserved.

Blogs

Get Your Shopping List Out Of The Rut!
by OncoLink Editorial Team
October 15, 2013

In Celebration of Eric Ott
by Bob Riter
August 17, 2015